BCAL Diagnostics Expands Breast Cancer Research With New Ethics Approval
BDX: $0.060 +0.00% · MC: $22M
BCAL Diagnostics has received ethics approval to expand its breast cancer research to multiomic assay development, including investigation of epigenomic biomarkers. Its lipidomics research framework has been published in a peer-reviewed journal, while a second paper remains under revision after peer review; an abstract on a blood-based assay for breast cancer recurrence has been accepted for a December symposium.

Comments